These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 33033619)

  • 1. COVID-IP: staring down the Bayh-Dole Act with 2020 vision.
    Paradise J
    J Law Biosci; 2020; 7(1):lsaa073. PubMed ID: 33033619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study.
    Treasure CL; Avorn J; Kesselheim AS
    Milbank Q; 2015 Dec; 93(4):761-87. PubMed ID: 26626985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms.
    Sarpatwari A; Kesselheim AS; Cook-Deegan R
    J Health Polit Policy Law; 2022 Dec; 47(6):879-895. PubMed ID: 35877952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Academic Medical Centers as Innovation Ecosystems: Evolution of Industry Partnership Models Beyond the Bayh-Dole Act.
    Silva PJ; Ramos KS
    Acad Med; 2018 Aug; 93(8):1135-1141. PubMed ID: 29668523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Stakes in Bayh-Dole: Public Values Beyond the Pace of Innovation.
    Valdivia WD
    Minerva; 2011 Mar; 49(1):25-46. PubMed ID: 21475661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Columbia University's Axel patents: technology transfer and implications for the Bayh-Dole Act.
    Colaianni A; Cook-Deegan R
    Milbank Q; 2009 Sep; 87(3):683-715. PubMed ID: 19751286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIH funding for patents that contribute to market exclusivity of drugs approved 2010-2019 and the public interest protections of Bayh-Dole.
    Ledley FD; Cleary EG
    PLoS One; 2023; 18(7):e0288447. PubMed ID: 37494368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MORE THAN MONEY: THE EXPONENTIAL IMPACT OF ACADEMIC TECHNOLOGY TRANSFER.
    McDevitt VL; Mendez-Hinds J; Winwood D; Nijhawan V; Sherer T; Ritter JF; Sanberg PR
    Technol Innov; 2014 Nov; 16(1):75-84. PubMed ID: 25061505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Realizing Public Rights Through Government Patent Use.
    Kapczynski A
    J Law Med Ethics; 2021; 49(1):34-38. PubMed ID: 33966648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intellectual property conundrum for the biological sciences.
    Olds JL
    Anat Rec B New Anat; 2004 Mar; 277(1):5-9. PubMed ID: 15052648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The valorization of non-patent intellectual property in academic medical centers.
    Marr K; Phan P
    J Technol Transf; 2020; 45(6):1823-1841. PubMed ID: 33012983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bayh-Dole Act turns 30.
    Loise V; Stevens AJ
    Sci Transl Med; 2010 Oct; 2(52):52cm27. PubMed ID: 20926832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protecting essential information about genetic variants as trade secrets: a problem for public policy?
    Juergens AK; Francis LP
    J Law Biosci; 2018 Dec; 5(3):682-705. PubMed ID: 31143458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. March-in rights under the Bayh-Dole Act: the NIH's paper tiger?
    O'Brien W
    Seton Hall Law Rev; 2013 Nov; 43(4):1403-32. PubMed ID: 24308083
    [No Abstract]   [Full Text] [Related]  

  • 15. Why did universities start patenting? Institution-building and the road to the Bayh-Dole Act.
    Berman EP
    Soc Stud Sci; 2008 Dec; 38(6):835-71. PubMed ID: 19227798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the role of R&D collaborations and non-patent IP policies in government technology transfer performance: Evidence from U.S. federal agencies (1999-2016).
    Hemmatian I; Ponzio TA; Joshi AM
    PLoS One; 2022; 17(5):e0268828. PubMed ID: 35609062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Care Efficiencies: Consolidation and Alternative Models vs. Health Care and Antitrust Regulation - Irreconcilable Differences?
    King MW
    Am J Law Med; 2017 Nov; 43(4):426-467. PubMed ID: 29452560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The COVID-19 pandemic and long-term incentives for developing vaccines: Patent law under stress.
    Kovac M; Rakovec L
    J World Intellect Prop; 2022 Mar; ():. PubMed ID: 35600091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incentives to promote the US pharmaceutical innovation: empirical research based on the case of Epogen.
    Zhang L; Wang J
    Drug Dev Ind Pharm; 2021 May; 47(5):820-824. PubMed ID: 34056986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crisis-Critical Intellectual Property: Findings From the COVID-19 Pandemic.
    Tietze F; Vimalnath P; Aristodemou L; Molloy J
    IEEE Trans Eng Manag; 2022 Oct; 69(5):2039-2056. PubMed ID: 35938060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.